Summary
Existing pharmaceutical methods can only target 15% of all proteins in the human proteome. Given this limitation, pharmaceutical companies are running out of options to develop effective drugs to tackle hard-to-treat diseases. To have a better chance of fighting these diseases, further targets of the remaining, so far undruggable 85% of our proteome need to be unlocked.
PROSION developed a disruptive platform of chemical building blocks called ProMs. The ProM-platform addresses a specific class of yet undruggable proteins linked to hard-to-treat-diseases. ProMs can be combined into small molecule drugs to target proteins that play a key-role in pathologies such as cancer, Alzheimer’s, cardiovascular diseases and immune mediated disorders.
The platform’s potential is currently being validated: in its first project, PROSION addresses a yet undruggable target to potentially provide new therapies for pancreatic and breast cancer and fight drug-resistance effects within cancer therapies.
PROSION developed a disruptive platform of chemical building blocks called ProMs. The ProM-platform addresses a specific class of yet undruggable proteins linked to hard-to-treat-diseases. ProMs can be combined into small molecule drugs to target proteins that play a key-role in pathologies such as cancer, Alzheimer’s, cardiovascular diseases and immune mediated disorders.
The platform’s potential is currently being validated: in its first project, PROSION addresses a yet undruggable target to potentially provide new therapies for pancreatic and breast cancer and fight drug-resistance effects within cancer therapies.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190154511 |
| Start date: | 01-04-2022 |
| End date: | 30-09-2024 |
| Total budget - Public funding: | 3 516 250,60 Euro - 2 461 375,00 Euro |
Cordis data
Original description
Existing pharmaceutical methods can only target 15% of all proteins in the human proteome. Given this limitation, pharmaceutical companies are running out of options to develop effective drugs to tackle hard-to-treat diseases. To have a better chance of fighting these diseases, further targets of the remaining, so far undruggable 85% of our proteome need to be unlocked.PROSION developed a disruptive platform of chemical building blocks called ProMs. The ProM-platform addresses a specific class of yet undruggable proteins linked to hard-to-treat-diseases. ProMs can be combined into small molecule drugs to target proteins that play a key-role in pathologies such as cancer, Alzheimer’s, cardiovascular diseases and immune mediated disorders.
The platform’s potential is currently being validated: in its first project, PROSION addresses a yet undruggable target to potentially provide new therapies for pancreatic and breast cancer and fight drug-resistance effects within cancer therapies.
Status
SIGNEDCall topic
HORIZON-EIC-2021-ACCELERATOROPEN-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
